Content about Genetics

December 13, 2013

A recent study commissioned by Intel revealed that patients are ready to embrace personalized care, all the way down to medications for their specific genetic makeup, and they want the freedom to get health care wherever and whenever it’s convenient for them.

Why is this important? Personalization — whether it is customized coupons and marketing or prescription medications — is here and will be critical in 2014. Consumers want more, and in the face of rising healthcare costs and a strained health care system, their healthcare is no exception.

A recent study commissioned by Intel revealed that patients are ready to embrace personalized care, all the way down to medications for their specific genetic makeup, and they want the freedom to get health care wherever and whenever it’s convenient for them.

December 10, 2013

Personalized medicine is on the horizon, and patients are not only awaiting it optimistically, but they also are willing to share a bit of personal information when it comes, according to a new study released Monday commissioned by Intel.

SANTA CLARA, Calif. — Personalized medicine is on the horizon, and patients are not only awaiting it optimistically, but they also are willing to share a bit of personal information when it comes, according to a new study released Monday commissioned by Intel. 

April 29, 2013

An organization focused on a fatal genetic disorder that affects men has launched a mobile app that allows for the location of clinical trials and clinics.

HACKENSACK, N.J. — An organization focused on a fatal genetic disorder that affects men has launched a mobile app that allows for the location of clinical trials and clinics.

November 19, 2012

The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

BETHESDA, Md. — The drug-discovery division of the Cystic Fibrosis Foundation is teaming up with drug maker Pfizer to find new treatments for patients with the most common genetic mutation of the disease.

October 20, 2011

Vertex Pharmaceuticals has filed for Food and Drug Administration approval of a drug for cystic fibrosis, the company said.

CAMBRIDGE, Mass. — Vertex Pharmaceuticals has filed for Food and Drug Administration approval of a drug for cystic fibrosis, the company said.

Vertex announced the submission to the FDA of an application for approval and priority review of Kalydeco (ivacaftor), which it said was potentially the first medicine to target the underlying cause of cystic fibrosis, namely mutations in the CFTR gene that causes defective or missing CFTR proteins that inhibit the flow of salt and water across cell membranes and lead to mucus buildup.

June 20, 2010

The Center for Genetics and Society recently praised the Food and Drug Administration's decision to...

March 7, 2010

A mid-stage clinical trial of a drug for muscular dystrophy got mixed results, developers Genzyme...